73 results
10-Q
2023 Q2
EX-10.3
SAVA
Cassava Sciences Inc
Quarterly report
3 Aug 23
4:35pm
10-Q
2023 Q2
EX-10.2
SAVA
Cassava Sciences Inc
Quarterly report
3 Aug 23
4:35pm
8-K
EX-10.1
SAVA
Cassava Sciences Inc
22 Nov 22
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
12:49pm
8-K
EX-10.1
SAVA
Cassava Sciences Inc
27 Oct 22
Cassava Sciences Announces Expansion of Leadership Team
4:03pm
10-Q
2022 Q2
EX-10.1
SAVA
Cassava Sciences Inc
Quarterly report
4 Aug 22
4:01pm
8-K
EX-10.1
u9w2ib
11 Mar 21
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
4:59pm
8-K
EX-10.1
u5p4c
12 Feb 21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
5:09pm
8-K
EX-10.1
aj3 0r4l8511oh
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
EX-10.1
rx6hj
10 Sep 20
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-10.1
yvbsq273de6f
1 Sep 20
Departure of Directors or Certain Officers
5:00pm
8-K
EX-10.1
0kt6y3odmmlnmaibw6
22 Mar 19
Termination of a Material Definitive Agreement
4:07pm
8-K
EX-10.1
1nk583g ujxtl6ug
11 Oct 18
Pain Therapeutics Announces Appointment of
4:12pm
8-K
EX-10.1
sueeva2 w9cy4v
20 Aug 18
Pain Therapeutics Announces Closing of $11.3 Million Registered Direct Offering
12:00am
8-K
EX-10.2
wfm4417l7srmnd9rlj4t
20 Aug 18
Pain Therapeutics Announces Closing of $11.3 Million Registered Direct Offering
12:00am
8-K
EX-10.1
a08gzmz3tz56a8orf7l
11 May 18
Departure of Directors or Certain Officers
5:29pm